The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 3: 343 - 348

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.03.011

Clinical Research

Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma

  • Shuang CHEN ,
  • Na YANG ,
  • Yudong HUANG ,
  • Xiangfeng KONG ,
  • Jintao LI ,
  • Yizhong TANG ,
  • Kexiong MA ,
  • Yangyang ZHANG ,
  • Yuandong ZHANG ,
  • Chengde REN
Expand
  • Department of Urology，Qinghai University Affiliated Hospital，Xining 810000，China

Received date: 2023-05-10

  Online published: 2024-02-22

Fold

Abstract

Objective To explore the relationship between serum miRNA-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma. Methods A total of 118 patients with renal clear cell carcinoma admitted to the Qinghai University Hospital from February 2019 to April 2021 were selected as the study subjects， and another 118 healthy patients in the same period as the control group. Real time fluorescence quantitative polymerase chain reaction （PCR） was used to detect the expression of miR-21 and miR-27b in the serum of all subjects. The relative expression levels of serum miR-21 and miR-27b between the patients with renal clear cell carcinoma and healthy control patients were compared. The expression and correlation of serum miR-21 and miR-27b in the patients with renal clear cell carcinoma of different pathological stages and Fuhrman grading were analyzed. The relationship between the expression of serum miR-21 and miR-27b and the survival and prognosis of the patients was explored as well. Results The expression levels of serum miR-21 and miR-27b in the patients with renal clear cell carcinoma were higher than those in the healthy control group （P < 0.05）. The serum miR-21 expression level in stage Ⅲ patients was higher than in stageⅠ（P < 0.05）， while the serum miR-21 expression level in the stage Ⅳ patients was higher than that in stagesⅠ，Ⅱ， and Ⅲ（P < 0.05）. The expression level of miR-27b in the serum of patients gradually increased across the four stages， with a significant difference （P < 0.05）. The pathological staging was positively correlated with the expression of miR-21 and miR-27b （P < 0.001）. The expression levels of miR-21 and miR-27b in serum of patients gradually increased across grades Ⅰ， Ⅱ and Ⅲ by Fuhrman grading， with significant difference （P < 0.05）. Fuhrman grading was positively correlated with the serum miR-21 and miR-27b expression （P < 0.001）. There was a statistically significant difference in the survival curve between the miR-21 high expression group and the low expression group （P < 0.05）. There was a statistically significant difference in the survival curve between the high expression group and the low expression group of miR-27b （P < 0.05）. Conclusion The expression levels of serum miR-21 and miR-27b in patients with renal clear cell carcinoma is indicative of the progression and prognosis of the patient's condition.

Key words： renal clear cell carcinoma; microRNAs; pathological staging; Fuhrman grading; survival prognosis

Cite this article

Shuang CHEN , Na YANG , Yudong HUANG , Xiangfeng KONG , Jintao LI , Yizhong TANG , Kexiong MA , Yangyang ZHANG , Yuandong ZHANG , Chengde REN . Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma[J]. The Journal of Practical Medicine, 2024 , 40(3) : 343 -348 . DOI: 10.3969/j.issn.1006-5725.2024.03.011

References

1 BAHADORAM S， DAVOODI M， HASSANZADEH S， et al. Renal cell carcinoma： an overview of the epidemiology， diagnosis， and treatment［J］. G Ital Nefrol， 2022，39（3）：13.
2 黄忠江，姜增誉，李健丁，等. 基于增强CT影像组学联合机器学习鉴别均质性肾透明细胞癌与肾乏脂肪血管平滑肌脂肪瘤［J］. 实用医学杂志， 2021，37（17）：2266-2270. doi:10.3969/j.issn.1006-5725.2021.17.020
3 POWLES T. Recent eupdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer： renal cell carcinoma： ESMO clinical practice guidelines for diagnosis， treatment and follow-up［J］. Ann Oncol， 2021，32（3）：422-423. doi:10.1016/j.annonc.2020.11.016
4 LJUNGBERG B， ALBIGES L， ABU-GHANEM Y， et al. European association of urology guidelines on renal cell carcinoma： the 2022 update［J］. Eur Urol， 2022，82（4）：399-410.
5 程力维，刘绪，袁晓露，等. MicroRNA-1271通过靶向mTOR抑制肾癌细胞的增殖和迁移［J］. 实用医学杂志， 2020，36（7）：895-901. doi:10.3969/j.issn.1006-5725.2020.07.013
6 吴国森，徐林熙，许振强，等. 微小RNA-140-5p下调Jagged1抑制肾透明细胞癌迁移、侵袭及血管生成［J］. 中华实验外科杂志， 2022，39（6）：1038-1041. doi:10.3760/cma.j.cn421213-20210925-01280
7 姚丽华，汪光蓉，蔡燕，等. miR-18a和miR-21在食管癌中的表达及其对食管癌的诊断价值［J］. 中华肿瘤杂志， 2019，41（2）：107-111. doi:10.3760/cma.j.issn.0253-3766.2019.02.006
8 高晓会，张亚利，张治业，等. miR-21靶向Atg5对非小细胞肺癌A549细胞自噬调控促进细胞增殖、迁移和侵袭的实验研究［J］. 临床肿瘤学杂志， 2019，24（2）：97-101. doi:10.3969/j.issn.1009-0460.2019.02.001
9 熊兵红，李莎莎，任紫阳，等. 生长停滞敏感基因5下调对结肠癌细胞生物学特性的影响及其机制［J］. 中华肿瘤杂志， 2022，44（11）：1168-1174. doi:10.3760/cma.j.cn112152-20200321-00243
10 杨旺盛，陆振刚，杨铎. miR-27b-3p调控TMBIM6对A549细胞凋亡影响［J］. 中华肿瘤防治杂志， 2020，27（20）：1622-1628.
11 宋殿芳，贾素敏，徐冲. LncRNA LINC00277通过与miR-27 b结合调控p53表达抑制宫颈癌细胞的侵袭和迁移［J］. 中国老年学杂志， 2021，41（18）：4079-4083. doi:10.3969/j.issn.1005-9202.2021.18.054
12 赵硕，李望. 肾癌患者血清中微小RNA-27b和胱抑素C、肌酐的表达水平及其临床意义［J］. 中华实验外科杂志， 2020，37（6）：1152-1154. doi:10.3760/cma.j.cn421213-20191127-01503
13 LJUNGBERG B， ALBIGES L， ABU-GHANEM Y， et al. European association of urology guidelines on renal cell carcinoma： the 2019 update［J］. Eur Urol， 2019，75（5）：799-810.
14 王榕，王成，陈阳，等. 肾细胞癌患者血清miR-135b5p表达变化的价值及功能［J］. 临床检验杂志， 2022，40（12）：912-917.
15 BEDKE J， ALBIGES L， CAPITANIO U， et al. The 2021 updated european association of urology guidelines on renal cell carcinoma： immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care［J］. Eur Urol， 2021，80（4）：393-397. doi:10.1016/j.eururo.2021.04.042
16 VANO Y A， ELAIDI R， BENNAMOUN M， et al. Nivolumab， nivolumab-ipilimumab， and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma （BIONIKK）： a biomarker-driven， open-label， non-comparative， randomised， phase 2 trial［J］. Lancet Oncol， 2022，23（5）：612-624. doi:10.1016/s1470-2045(22)00128-0
17 RATHMELL W K， RUMBLE R B， VAN VELDHUIZEN P J， et al. Management of metastatic clear cell renal cell carcinoma： ASCO guideline［J］. J Clin Oncol， 2022，40（25）：2957-2995. doi:10.1200/jco.22.00868
18 AMBROSETTI D， COUTTS M， PAOLI C， et al. Cancer-associated fibroblasts in renal cell carcinoma： implication in prognosis and resistance to anti-angiogenic therapy［J］. BJU Int，2022，129（1）：80-92. doi:10.1111/bju.15506
19 赫志强，王雷，杨锦建. 长链非编码RNA氧化应激反应丝氨酸丰富1反义RNA 1对肾癌细胞增殖、迁移及侵袭的影响［J］. 中华实验外科杂志， 2021，38（3）：488-492. doi:10.3760/cma.j.cn421213-20200821-01707
20 WOLF M M， KIMRYN R W， BECKERMANN K E. Modeling clear cell renal cell carcinoma and therapeutic implications［J］. Oncogene， 2020，39（17）：3413-3426. doi:10.1038/s41388-020-1234-3
21 YAO D， HE Q， SUN J， et al. FGF21 attenuates hypoxia?induced dysfunction and inflammation in HPAECs via the microRNA?27b? mediated PPARgamma pathway［J］. Int J Mol Med， 2021，47（6）：116. doi:10.3892/ijmm.2021.4949
22 SITU Y， XU Q， DENG L， et al. System analysis of VEGFA in renal cell carcinoma： The expression， prognosis， gene regulation network and regulation targets［J］. Int J Biol Markers， 2022，37（1）：90-101. doi:10.1177/17246008211063501
23 MENG K， LI Z， CUI X. Three LHPP gene-targeting co-expressed microRNAs （microRNA-765， microRNA-21， and microRNA-144） promote proliferation， epithelial-mesenchymal transition， invasion， and are independent prognostic biomarkers in renal cell carcinomas patients［J］. J Clin Lab Anal， 2021，35（12）：e24077. doi:10.1002/jcla.24077
24 PUENTE J， LAINEZ N， DUENAS M， et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma［J］. Oncotarget， 2017，8（18）：30410-30421. doi:10.18632/oncotarget.16494
Options
Outlines

/

〈 〉